Xeljanz 5mg ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	2

46. 悪性関節リウマチ

---

臨床試験数 : 4,356 /  薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03868072 (ClinicalTrials.gov)	February 22, 2019	6/3/2019	Study to Evaluate the Bioequivalence of Pfizer Korea Inc. XELJANZ 5Mg Tablet in Healthy Volunteers	An Open-label, Randomized, Fasted, Single Dose, Crossover Study to Evaluate the Bioequivalence of Chong Kun Dang Pharmaceutical Chong Kun Dang Tofacitinib Tablet and Pfizer Korea Inc. XELJANZ 5Mg Tablet in Healthy Volunteers	Rheumatoid Arthritis	Drug: XELJANZ 5Mg Tablet;Drug: Chong Kun Dang Tofacitinib Tablet	Chong Kun Dang Pharmaceutical	NULL	Completed	19 Years	N/A	All	40	Phase 1	Korea, Republic of
2	EUCTR2018-003162-13-IT (EUCTR)	23/01/2019	08/11/2018	A Study to investigate Bone turnover Markers in patients planned to receive tofacitinib	A Study to investigate Bone turnover Markers in patients planned to receive tofacitinib - WI232128	Rheumatoid arthritis MedDRA version: 20.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: XELJANZ 5 mg film-coated tablets Product Name: Xeljanz 5mg INN or Proposed INN: TOFACITINIB	AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Italy